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by G-BA, due to the high methodological standards set by G-BA and IQWiG, manu-
facturers should de-prioritize this endpoint.
PCN254
Media Coverage of the NiCe first draft CoNsultatioN guidaNCe for 
trastuzuMab eMaNtaNsiNe (KadCyla) iN breast CaNCer
Macaulay R.
HERON Commercialization, London, UK
Objectives: The National Institute of Health and Care Excellence (NICE) makes 
recommendations on which drugs the National Health Service (NHS) should fund, 
with cost-effectiveness being a key criterion. There have been critical media reac-
tions toward NICE appraisals that recommend against funding drugs (particularly 
oncologics), perhaps the most memorable example of which relates to the funding 
of Herceptin in early-stage breast cancer in 2005. This research aimed to evaluate 
how the media currently report NICE decision-making, focussing on the NICE 
appraisal consultation document not recommending Kadcyla on 23rdApril 2014 
with a cost per Quality Added Life Year (QALY) > £180,000, far exceeding typical 
NICE approval thresholds (~£30,000/QALY). MethOds: A selection of national and 
regional newspaper websites, UK broadcasters, press agencies, pharmaceutical 
trade and medical publications were screened for any articles published between 
23rd-25thApril 2014 regarding this NICE draft guidance from which key criteria 
were extracted and compared. Results: 19 articles were extracted (6 national 
newspapers, 6 regional newspapers, 3 broadcasters, and 4 other). 7/19 articles 
primarily focussed on the reaction of a patient/doctor, all of whom were particu-
larly critical of the NICE decision. 3/19 focussed on the high proposed cost of the 
new drug, 2 of which were critical of the pharmaceutical company. 9/19 followed 
the format of briefly summarising the decision and drug, with the majority of 
the article comprising reactions from various sources. However, there was an 
overall numerically higher number of sources in each article criticizing NICE (38, 
mean 2.0 per article) than those defending the NICE decision (21, mean 1.1 per 
article). cOnclusiOns: NICE decisions not to fund oncology drugs still seem to 
be predominantly faced by a hostile media reception that focus more on patient 
reactions than the difficulties of how to allocate finite health care resources to 
best optimise care in the NHS.
PCN255
CoMPariNg how siNgle arM Phase ii trial data CaN suPPort aPProval 
of oNCologiCs by euroPeaN health teChNology assessMeNt bodies
Macaulay R.
HERON Commercialization, London, UK
Objectives: The European Medicines Agency (EMA) approved 15 oncologics across 
24 indications based on pivotal single-arm Phase II data (Macaulay, ISPOR Dublin 
2013). Approval was typically granted for indications in which there was no thera-
peutic alternative where a response rate of ≥ 35% was demonstrated. This research 
aims to compare how such data can further support approval between different 
European Health Technology Agencies (HTAs). MethOds: Relevant National 
Institute of Health and Care Excellence (NICE), Scottish Medicines Commission 
(SMC), Commission de la Transparence (CT), Institute for Quality and Efficiency 
in Health Care (IQWiG), Federal Joint Committee (G-BA), and Swedish Dental and 
Pharmaceutical Benefits Agency (TLV) reports were sourced for any oncologic 
approved by the EMA on the basis of pivotal Phase II data (up to March 2014) and 
the decision and key rationale were analysed. Results: CT fully reimbursed 14/14 
(100%) oncologics appraised on the basis of pivotal Phase II data, with 10/14 obtain-
ing ASMRs I-III. In Germany (IQWiG), 6/6 (100%) oncologics appraised on this basis 
were deemed to offer some added benefit, avoiding reference pricing (5/6 were 
orphan drugs which are not subject to a benefit assessment). NICE approved 5/7 
(71%), SMC 6/11 (55%), and TLV 7/7 (100%) of oncologics appraised on Phase II data. 
For NICE/SMC/TLV rejected drugs, the clinical case was not strongly criticised, rather 
cost-utility values were deemed too high and uncertain. Even for approved drugs, 
the lack of comparative data was critiqued as introducing considerable uncertainty 
to submissions. cOnclusiOns: For any oncologic approved by the EMA on the basis 
of Phase II data, favourable ASMR and benefit ratings can be awarded on this basis 
by the CT and IQWiG/G-BA, respectively. NICE, SMC, and TLV recommendations are 
conditional on cost-effectiveness being adequately demonstrated with additional 
price discounts required to offset inherent uncertainties in cost-utility modelling 
from such limited clinical data.
PCN256
CoMPariNg aCCess to drugs through the Cdf aNd by NiCe – the Cdf 
stiPulate striCter CliNiCal Criteria but will also aPProve fuNdiNg 
for off-label usage
Macaulay R.
HERON Commercialization, London, UK
Objectives: The Cancer Drugs Fund (CDF) was set up in 2011 in England to enable 
cancer patients to gain access to therapies that are not routinely available on the 
NHS. However, this fund has been criticised for providing funding for therapies 
that have not been shown to be cost-effective by the National Institute for Health 
and Care Excellence (NICE). This research aims to define how restrictive criteria 
are for accessing drugs under the CDF and how this compares to access under 
NICE. MethOds: A systematic review of the criteria for accessing drugs accord-
ing to the national CDF list was undertaken and was compared to NICE-published 
statistics for oncology technology appraisals up to 31st March 2014. Results: 
80 oncologic indications have been approved under the CDF, each with specific criteria 
for access and usage. Overall, an average of 5.0 (range 3-11) criteria were specified for 
each drug. Typically, 3 criteria were specified for all drugs: 1) consultant specialist pre-
scriber; 2) specifying the disease; and 3) the line of therapy. However, many agents had 
additional restrictions on top of this, including 20/80 (25%) specifying the performance 
status (14 had 0-1; 6 had 0-2) and 12/80 (15%) to be used within the treating Trust’s 
governance framework as these drugs were not licensed in the specified indication. 
recommendations. Its Dutch counterpart, ZI, issued only 8% of negative decisions 
to TCTs. The mode for a success rate in the Netherlands was special policy that 
enabled reimbursement of TCTs without CEA.
PCN251
the CaNCer drugs fuNd: a systeMatiC aNalysis of the requireMeNts 
for iNClusioN oN the eNglish NatioNal list of drugs for Priority 
fuNdiNg
Macaulay R.
HERON Commercialization, London, UK
Objectives: The Cancer Drugs Fund (CDF) was set up in 2011 in England to enable 
patients to access therapies that are not routinely available on the National Health 
Service (NHS). In April 2013, NHS England became responsible for the management 
of the CDF with a single national list of drugs for prioritised funding. As the CDF 
has recently been extended to 2016, it is increasingly important to understand 
the key criteria for inclusion on the CDF-approved list, which this research aims 
to define. MethOds: CDF appraisal reports were sourced from the NHS England 
website (April 2013 – March 2014) and the date, decision, and key rationale were 
extracted. Results: 56 CDF decision summaries were available, 14 (25%) received 
full approval, 10 (18%) received conditional/restricted approval, 28 (50%) were 
rejected, and 4 (7%) were referred to commissioning. The key clinical attributes 
of each oncologic were given a numerical scoring that sum to a possible maxi-
mum +21 and minimum -4. The maximum score of any drug appraised was +8 
and the minimum was -1. Excluding appraisals referred to commissioning, 16/18 
appraisals scoring < 2 were rejected (89%) compared to only 5/25 (20%) scoring > = 2 
(4/5 primarily due to trial comparator choice). 9 were not scored due to a lack of 
appropriate evidence. 11 submissions were only based on Phase II data (for such 
submissions, efficacy scores were halved), 5 of which were approved. cOnclusiOns: 
A score of > = 2 seems to be the key clinical threshold above which most 
drugs are CDF-approved, below which most are rejected. Given that 43/47 scoring 
drugs scored -1 for toxicity, this means that 3 points are typically required, which 
can come through a 4-5 month Progression Free Survival or Overall Survival gain (or 
a 2-3 month gain in both), but this must be versus the clinically relevant comparator.
PCN252
testiNg the utility of the Nhs’s systeMiC aNti-CaNCer theraPy data 
set for Multi-iNdiCatioN PriCiNg
McNamara L., McNamara S.
Roche Products Ltd., Welwyn Garden City, UK
Objectives: The price of a medicine should reflect the value it offers to patients, 
the health care system and society more broadly. However, with current pricing 
manufacturers can only set the price of a product based upon the cost per unit of 
that product. This may result in a price being set which society considers as being as 
‘too high’ in certain indications. This apparent mismatch in value and cost can lead 
to patients being denied access to medicine in certain indications. MethOds: The 
implementation of a pricing model where there is differentiated value of a medi-
cine across indications, line of therapy or if used as a mono/combination therapy 
requires the use of real world drug utilisation data. The Personalised Reimbursement 
Models project is at the forefront of the development and implementation of innova-
tive pricing approaches in the UK. This project includes identifying and developing 
the infrastructure required in order to introduce Multi-Indication Pricing (MIP) into 
the NHS in the UK. We have worked alongside NHS Trusts and national bodies in 
a joint working project to validate and test the utility of the Systemic Anti-Cancer 
Therapy (SACT) dataset. Results: This joint working project demonstrates that 
SACT has the potential to allow implementation of MIP in England. cOnclusiOns: 
Following completion of this work we hope SACT will be used to introduce MIP in 
England - this will eliminate the administrative pharmacy burden of data collection 
for commercial schemes for cancer medicines, enabling medicines to be priced 
for the value they provide in each of their uses and ensure that patients are not 
disadvantaged due to having a condition potentially treatable by a product with 
multiple indications.
PCN253
oNCology ProduCts iN the aMNog ProCess – learNiNgs for a 
suCCessful dossier subMissioN
Dehnen J., Goldhagen K.
IMS Consulting Group, Muenchen, Germany
Objectives: Since AMNOG reform has taken effect 3.5 years ago, 78 dossiers have 
been evaluated by the G-BA. Especially with oncology agents, 28 products have 
started the process and G-BA has finalized decisions for 25 dossiers. In 20 cases addi-
tional benefit was granted. Therefore, the success rate of oncology products is 80% 
and much higher than the success rate of non-oncology products (29%). MethOds: 
An analysis of all oncology assessments will reveal key drivers responsible for the 
positive assessments by IQWiG and G-BA. Beside the study design (H2H vs. indirect 
comparison), and comparator choice the analysis will focus on submitted end-
points. It will be evaluated which endpoints contribute most in oncology indications 
to additional benefit. Results: Additional benefit is assessed based on patient 
relevant endpoints (mortality, morbidity, quality of life & safety). More than 55% 
of submitted endpoints fall in the safety category, followed by morbidity (approx. 
30%), mortality (approx. 10%) and quality of life (approx. 5%). The most important 
endpoint is mortality (OS), where the G-BA granted additional benefit in 18 out 
of 20 dossiers primarily based on OS data. In terms of morbidity, PFS, ORR and 
“Time to Pain Progression” are the top three most submitted morbidity endpoints; 
however, only “Time to Pain Progression” led to additional benefit in 2 out of 3 
cases. Only in one case quality of life contributed to the overall additional benefit 
decision. cOnclusiOns: OS will continue to be the most additional benefit con-
tributing endpoint in oncology. In the absence of OS, PFS will not help in the overall 
additional benefit decision by G-BA, unless the MNF can justify PSF to be patient 
relevant according to IQWiG methodology. Although QoL is an accepted endpoint 
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additional 6% to 11% of variance), however carer characteristics only emerged as a 
significant predictor of the health burden scale (11% of explained variance). Key indi-
vidual predictor variables of burden domains included patients’ general health sta-
tus, presence of a stoma, and the time costs associated with care. cOnclusiOns: 
These results highlight the need to recognise the role that various factors play in 
determining carer burden. While certain aspects of carer characteristics influence 
this, patient health and care-related activities have the most significant impact 
pointing to a need to deliver effective support to those most at risk of carer burden.
PCN260
iNvestigatiNg the use of PersoNalised MediCiNe iN CaNCer trials – aN 
uPdate
Hamilton K.A., Wilson T.
Costello Medical Consulting Ltd., Cambridge, UK
Objectives: Personalised medicine continues to be a hot topic in health care evalu-
ation, particularly in diseases where response to therapy within the patient popula-
tion is often heterogenous. The results of an analysis previously presented at ISPOR 
showed that the proportion of cancer trials investigating personalised medicine 
rose 7-fold between 2000 and 2010. However, in 2011, this trend appeared to have 
reached a plateau, with the proportion of cancer trials considering personalised 
medicine settling at around 15-20%. The aim of this study was to update the previous 
research to take account of the proportion of cancer trials which included personal-
ised medicine between 2012 and 2013, inclusive, to assess whether this pattern has 
changed in more recent years. MethOds: Terms including ‘diagnostic’, ‘prognostic’ 
and ‘biomarker’ were used to search ClinicalTrials. gov for all interventional cancer 
trials which started between 2012 and 2013 and considered the use of individualised 
medicine. These trials were then compared to those of all interventional cancer tri-
als listed on ClinicalTrials. gov starting in the same period. Results: Of all cancer 
trials analysed between 2000 and 2013, inclusive, 3,664 of 25,203 (14.5%) consid-
ered personalised medicine. Although the previous analysis showed a substantial 
increase in this proportion between 2000 and 2010, this trend does not appear to 
continue into the current decade. The proportion of trials considering personalised 
medicine identified in this update was consistent with that seen in 2011, with 17.7% 
of trials in 2012 and 18.8% in 2013 considering personalised medicine, perhaps sig-
nifying a lack of further increase in research interest. cOnclusiOns: Surprisingly, 
in spite of the apparent drive and enthusiasm for the use of personalised medicine 
within the medical community, these results indicate that the proportion of such 
trials may have reached a plateau. Therefore, this might suggest that cancer research 
is continuing to focus on traditional, non-personalised interventions.
PCN262
the role of Prior breast CaNCer diagNosis iN artiCulatiNg 
exPeCtatioNs for reCoNstruCted breast aPPearaNCe
Scott A.M.1, Lawson J.L.2, Mazza M.C.3, Rubin L.R.3
1Memorial Sloan Kettering Cancer Center, New York, NY, USA, 2Yeshiva University, Bronx, NY, 
USA, 3The New School for Social Research, New York, NY, USA
Objectives: Women who undergo mastectomy, whether due to a first-time breast 
cancer diagnosis or recurrence, are often presented with the option of breast recon-
struction. Decisions whether to undergo reconstruction are informed by women’s 
surgery expectations, which develop based on many factors, including past knowl-
edge and experience. The aim of this study was to examine the impact of previous 
breast cancer diagnosis on a women’s approach to expectation-identification of their 
reconstructed breast appearance. MethOds: This study was performed using cross-
sectional data as part of a larger field-test. Expectations scales of the BREAST-Q PRO 
were administered in a clinical setting to breast cancer patients seeking immediate 
breast reconstruction. Responses were categorized into specific (unlikely, somewhat 
likely, very likely) or vague expectations (don’t know) as the dependent variable. The 
independent variable was defined as previous or primary diagnosis. Chi Square and 
one-way ANOVA were performed using SPSS22. Results: The study sample (n = 62; 
response rate, 66%) was characterized by a mean age of 49.6 ± 9.2 years, 82.3% married, 
77.4% employed and 79.0% Caucasian. Twenty-three (37.1%) had a history of previous 
breast cancer diagnosis without mastectomy. Women who had previous breast cancer 
diagnosis were more likely to select a specific expectation in response to what their 
new breast (s) would look like in the mirror clothed (ETA squared; 0.11, P= 0.011) and 
unclothed (ETA squared; 0.09, P= 0.017) one year after reconstruction. cOnclusiOns: 
Expectancies guide perception, so that people tend to focus on events that are congru-
ent with their expectations. In our study, women undergoing breast reconstruction 
were more likely to identify a specific expectation about the appearance of their 
reconstructed breast if they had been previously diagnosed with breast cancer. More 
research is needed to determine additional factors that may mediate the develop-
ment of preoperative surgical expectations. Such information will aid in facilitating 
patient-physician communication.
PCN263
NiCe restriCtiveNess CoMPared to the MarKet authorizatioN iN 
oNCology aNd NoN-oNCology reviews
Jaksa A., Westbrook L., Rubinstein E., Daniel K., Ho Y.S.
Context Matters, Inc., New York, NY, USA
Objectives: To determine how often NICE recommendations are more restric-
tive than market authorizations in oncology reviews compared to non-oncology 
reviews. MethOds: 161 NICE Technology Appraisal decisions from 2007-2013 were 
evaluated; 95 non-oncology and 66 oncology reviews. For each generic drug included 
in a review, the corresponding brand and market authorization was retrieved from 
the EMA or MHRA. NICE positive decisions were compared to the market authoriza-
tions. Any decision that included language that restricted the population eligible for 
treatment or reimbursement for a given therapy was categorized as “recommend 
with restrictions.” NICE positive decisions that were not more restrictive than the 
market authorizations were categorized as “recommend.” Negative decisions were 
categorized as “do not recommend.” Results: Oncology reviews were more likely to 
By comparison, only 7/88 (8%) of NICE-approved cancer appraisals have been subject 
to restrictions in addition to the label. cOnclusiOns: Access to anti-cancer drugs 
under the CDF tends to be more restrictive than those approved by NICE. Thus, attain-
ing NICE approval for CDF-approved drugs could broaden clinical access as well as 
ensuring reimbursement after the fund is due to close in 2016. Nevertheless, the CDF 
does provide a formal mechanism under which reimbursement can be provided for 
off-label use of cancer drugs, which NICE will not consider.
PCN257
aPPliCatioN of threshold value for Cost-effeCtiveNess iN 
reCoMMeNdatioNs issued by ageNCy for health teChNology 
assessMeNt iN PolaNd for CaNCer drug teChNologies
Zawodnik A., Matusewicz W.
Agency for Health Technology Assessment in Poland (AOTM), Warsaw, Poland
Objectives: To analyse HTA recommendations for cancer drug technologies issued 
by Agency for Health Technology Assessment (AHTAPol) in Poland and to verify if 
official threshold value for cost-effectiveness is respected. MethOds: The review 
of HTA recommendations concerning cancer technologies issued by AHTAPol in the 
period from January 2012 to March 2014 was preformed. The classification of HTA 
recommendations based on Raftery’s approach labeling them as positive, positive 
with major or minor restriction and negative was conducted. Decisions and ICURs 
values from each recommendation were compared to the official threshold value for 
cost-effectiveness (in Poland defined as 3xGDP for each year) and defined whether 
the ICUR value is either above or below the official threshold. Other aspects of 
recommendations, such as criterion for decision, type of RSS implemented and 
reasons for restrictions were also analysed. Results: In the studied period AHTAPol 
issued 46 recommendations for 35 different cancer drugs (due to the multiplied 
recommendations for 4 drugs). After review, 32 recommendations with calculated 
ICUR (with Risk Sharing Scheme (RSS) if implemented) were included in the analy-
sis. For 11 of 13 negative recommendations ICUR values were placed above offi-
cial AHTAPol’s threshold. For 7 of 11 positive recommendations ICUR values were 
placed below threshold. On the other hand, for 5 of 7 positive recommendations 
with major restriction ICUR values were placed above official threshold. However, 
restrictions were related to the unacceptable cost-effectiveness. The same analysis 
for the ICUR values without implementation of RSS was conducted to compare the 
results. cOnclusiOns: The official threshold values set in AHTAPol are respected 
in the majority of decisions for cancer drugs. Cost-effectiveness is one of the most 
important criterion of decisions made by AHTAPol. Clinical effectiveness, safety and 
specificity of end-of-life extending medicines were also considered.
PCN258
PriCe CoNtrol of out-PatieNt CaNCer drugs iN bulgaria, 2010-2011: 
refereNCe based PriCiNg aNd PubliC teNders versus refereNCe based 
PriCiNg oNly
Djambazov S.N.1, Vekov T.Y.2, Petrov D.3
1Cancer clinics Doc Dr Valentina Tsekova, Sofia, Bulgaria, 2Medical University Pleven, Pleven, 
Bulgaria, 3Bulgarian Medical Union, Sofia, Bulgaria
Objectives: To compare drug prices and public expenditure of out-patient cancer 
drugs between two consecutive periods: reference based pricing (RBP) and public 
tendering at MoH in 2010 and RBP only in a positive drug list (PDL) at the National 
Health Insurance Fund (NHIF) in 2011. MethOds: We compared the prices of the 40 
products, which are used in out-patient setting. We used public documents like ten-
der results from 2010 MoH tender and reimbursement list of NHIF in 2011. Results: 
70% of the products (n= 28) were with higher prices, 20% had no price change (n= 8) 
and 10% (n= 4) had lower prices in 2011. In 2010, 15% (n= 6) had 50% lower prices 
than same products’ prices in the PDL in 2011. For 10% of the products (n= 4) in 
2010, after tendering, the MoH paid higher prices than the registered prices after 
RBP. These were patented products, without generic competition. In 2011, NHIF paid 
BGN 18.591.365 for these 40 drugs. For the same quantities, with MoH 2010 prices, 
the public expenditure could be BGN 10.788.430 (42% lower). cOnclusiOns: Public 
tendering achieved lower prices than RBP alone. For patented products, without 
generic competition, tendering is not the ultimate solution. Tendering should be 
used with caution, as it can drive some producers out of the market and create 
non-competitive environment with counter-productive results. Frequent changes 
of the laws and regulations, without budget impact analysis, is like gambling. Long-
term national drug pricing policy is hardly needed and should be strictly followed.
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uNderstaNdiNg Caregiver burdeN iN ColoreCtal CaNCer: what role 
do PatieNt aNd Carer faCtors Play?
Maguire R.1, Hanly P.1, Hyland P.1, Sharp L.2
1National College of Ireland, Dublin, Ireland, 2National Cancer Registry Ireland, Cork, Ireland
Objectives: This study aimed to explore the key determinants of caregiver burden 
in colorectal cancer (CRC) carers. Specifically we analysed the effect of (i) patient 
health (ii) care-related activities, and (iii) carer characteristics, as predictors of four 
distinct aspects of carer burden. MethOds: 495 CRC survivors (response rate = 39%) 
diagnosed 2007-2009 completed a questionnaire which collected information on 
socio-demographic characteristics, as well as disease and treatment-related factors. 
General health status was measured using the EORTC QLQ30.228 of these survivors 
indicated that they had informal carers who were then sent a questionnaire includ-
ing questions on socio-demographic factors, health status and care-related costs 
as well as the Caregiver Reaction Assessment (CRA) scale. Hierarchical multiple 
regression analysis was used to assess the impact of patient factors, care-related 
activities and carer characteristics on four burden elements within the CRA (family 
support, finances, schedule, and health). Results: 153 carers completed the carer 
questionnaire and were included in the analysis with their corresponding patients. 
Patient characteristics and disease-related factors were the strongest predictor of 
all four aspects of caregiver burden ranging from 14% to 22% of explained variance. 
Care-related activities also significantly predicted burden scores (explaining an 
